Celcuity (CELC) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.21

Estimate

-$1.53

Surprise

+21.2%

Score today

5.1/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Celcuity (CELC) reported a narrower loss than forecast — adjusted EPS of -$1.21 against the -$1.53 estimate (a 21.2% beat on a still-unprofitable quarter).

• Guggenheim Maintains Buy on Celcuity, Lowers Price Target to $169 — benzinga, 2026-11-06
• Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update — fiscal.ai, 2026-11-05
• Celcuity Q3 2026 Earnings Call Transcript — benzinga, 2026-11-05

TrendMatrix currently rates CELC Sell at 5.1/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +21.2% surprise compares with a +8.5% four-quarter average. Next scheduled report: 2027-03-24.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$66.79

Price target

$132.86

Stop

$62.11

Upside to target

+98.9%

Reward-to-risk

6.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$3.27B

P/E (fwd)

-136.3

52-week range

$53.54–$151.02

Off 52-week high

55.8%

RSI (14)

68

Volume vs avg

0.67×

Score today

5.1/10